AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:33:53 2024-04-24 am EDT			5-day change	1st Jan Change
11,390 ^GBX	+1.08%		+4.86%	+7.45%

01:38pm	ASTRAZENECA : Bernstein reiterates its Buy rating	ZD
11:34am	Angle shares jump on supplier agreement with with AstraZeneca	AN

ASTRAZENECA : Oddo downgrades from Buy to Sell

June 22, 2020 at 06:38 am EDT

Oddo's analyst downgrades rating of ASTRAZENECA from Buy to Sell. The target price is revised downwards from GBX 8100 to GBX 7600.

Latest news about AstraZeneca PLC

ASTRAZENECA : Bernstein reiterates its Buy rating	07:38am	ZD
Angle shares jump on supplier agreement with with AstraZeneca	05:34am	AN
AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook	05:12am	AN
Angle PLC Announces New Commercial Agreement with AstraZeneca PLC	02:00am	CI
AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder	Apr. 23	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Apr. 23	ZD
AstraZeneca: Voydeya approved in the EU as a treatment for HPN	Apr. 23	CF
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease	Apr. 23	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
AstraZeneca: presents new data at ECCMID	Apr. 17	CF
The market is pinning its hopes on earnings reports	Apr. 17
ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Market sentiment sours	Apr. 16
ASTRAZENECA : Deutsche Bank returns to 'Hold	Apr. 16	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	Apr. 16	MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial	Apr. 16	CI
ASTRAZENECA : Deutsche Bank drops its Sell rating	Apr. 16	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
RBC raises Admiral; Barclays cuts Phoenix Group	Apr. 16	AN
AstraZeneca: improvements in biliary tract cancer	Apr. 16	CF
AstraZeneca's hails Imfinzi survival data on cancer form	Apr. 16	AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial	Apr. 16	MT
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

140.2 USD

Average target price

161.5 USD

Spread / Average Target

+15.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+7.40%	217B
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+26.82%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
NOVARTIS AG	+6.43%	199B
ROCHE HOLDING AG	-9.04%	204B
PFIZER, INC.	-8.58%	149B
AMGEN INC.	-4.99%	147B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Oddo downgrades from Buy to Sell

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals